Safety Study of AMG 557 in Subjects With Lupus Arthritis

This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.

Lead sponsor: Amgen•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment20

Start dateJun 2012

Last updatedJan 24, 2017

Condition

Lupus Arthritis, Systemic Lupus Erythematosus

Locations shown

Research Site

Los Angeles, California

Research Site

San Leandro, California

Research Site

Danbury, Connecticut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2017Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety Study of AMG 557 in Subjects With Lupus Arthritis

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Trial snapshot

Condition

Locations shown

For caregivers